Health Benefits Hub

September 15, 2021

Drug Plans Decoded: Biosimilars Part 1.

By the Pharmacy Consulting Team at TELUS Health Biosimilars 101: what you need to know. Four provinces so far have implemented or are implementing mandatory switching policies to boost the utilization of biosimilar drugs. B.C. and Alberta were first in 2019, followed by New Brunswick and, most recently in May […]

Sign up for email updates.

All the latest articles delivered directly to your inbox.

Sign up

We will use your email address to send you our newsletter.
All communications will be from TELUS Health.

All fields are required

First name

Last name

Language

Company Name

Job title

Select the option that best describes your role

We will use your email address to send you our newsletter. All communications will be coming from TELUS Health. Our contact information is: 630 René-Lévesque Blvd. West, 22nd floor, Montreal, QC J4K 5B1. Email: telushealth@telus.com. Phone: 1-877-999-4669. We assure you that your email address will not be shared with any third party. You can withdraw your consent to receive electronic messages from TELUS Health at any time.

August 11, 2021

Keep up with current industry trends.

Drug Plans Decoded: Biosimilars Part 1.

Canadian Drug Landscape Update: Spring 2021 Webinar.

Insights into the cost-effectiveness for cell and gene therapies.

Humanizing the Future of Work.